Fat hormone linked to progression of fatty liver disease may hold key to new treatments

November 6, 2017, University of Michigan
Credit: CC0 Public Domain

The rising obesity epidemic has brought with it an army of maladies. One, in particular, is threatening to outpace many of the disorders that accompany obesity, in terms of occurrence and severity: nonalcoholic fatty liver disease.

"I think in the coming decades, it's going to be a bigger problem than even diabetes," said University of Michigan cell biologist Jiandie Lin, senior author of a new study that identified a key driver of the progression to the most harmful form of the disease—nonalcoholic steatohepatitis, or NASH.

The international team of researchers led by U-M found that increasing the levels of the fat Neuregulin 4 (Nrg4) protected from metabolic stress in mice. Loss of this hormone had the opposite effect; mouse livers deteriorated and progressed to NASH more quickly.

The findings, scheduled for publication Nov. 6 in the Journal of Clinical Investigation, led the researchers to believe that Nrg4 may be an effective target for therapeutic intervention.

Fatty disease represents a spectrum of disorders, ranging from relatively harmless benign fatty liver to potentially life-threatening NASH—which results in chronic inflammation, and fibrosis, increasing the risk of cirrhosis and .

More than a third of U.S. adults and up to 10 percent of children have some form of fatty liver disease. In up to 20 percent of these patients, the liver cells begin dying, and the disease develops into NASH. And the problem is growing.

"The estimate is that by 2020, NASH will be the leading cause of the need for , surpassing hepatitis and ," said Lin, a faculty member at the U-M Life Sciences Institute, where his lab is located, and at the U-M Medical School. "And there are currently no drugs available that can treat it."

Despite this rising occurrence of fatty liver disease, scientists did not have a clear picture of what keeps cells healthy and stable under obesity-related stress in some patients, and what leads to cell death—and the progression to NASH—in others.

To address this question, Lin and his colleagues evaluated the effects of Nrg4 in mice that had been fed the type of high-fat, high-sugar diet that leads to fatty liver disease.

"When the hormone was elevated, we saw less cell death, less inflammation, less fibrosis," said Liang Guo, a researcher in Lin's lab and the lead author of the study. "On the other hand, mice lacking the hormone fare much worse. The hormone is having a distinct function that limits cell death and prevents progression to the most severe fatty liver ."

The findings expand on a previous study from Lin's lab that showed Nrg4 could prevent the liver from converting sugar into fat, lowering the risk of at its outset.

"We're now seeing that it performs two major activities," Lin said. "It not only regulates metabolism by reducing liver fat accumulation, but it's also keeping the liver healthy. And by doing that, it can actually prevent the progression into NASH."

And there's more good news: The researchers have not yet seen any negative side-effects in the mice with increased Nrg4. Lin's lab is now focused on further testing the therapeutic viability of the hormone in treating NASH.

Explore further: Fatty liver: Turning off TAZ reverses disease

More information: Liang Guo et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI96324

Related Stories

Fatty liver: Turning off TAZ reverses disease

October 27, 2016
Scientists at Columbia University Medical Center (CUMC) have identified a factor in liver cells that is responsible for turning a relatively benign liver condition, present in 30 percent of U.S. adults, into a serious disease ...

Study sheds light on immune responses driving obesity-induced liver disease

June 28, 2017
New findings from mouse models reveal that the type of immune response that helps maintain healthy metabolism in fatty tissues, called type 2 immunity, also drives obesity-induced nonalcoholic fatty liver disease (NAFLD). ...

Inflammatory signature of nonalcoholic fatty liver disease

May 16, 2017
A team of investigators led by Rohit Kohli, MBBS, MS, of Children's Hospital Los Angeles, has identified key inflammatory cells involved in nonalcoholic fatty liver disease. Current treatment for the disorder involves changes ...

Hormone identified that limits liver fibrosis

October 13, 2016
Nonalcoholic steatohepatitis (NASH) has been emerging worldwide and effective treatment, especially for liver fibrosis, is essential for improving the prognosis. A Japanese research team has identified and clarified the mechanism ...

Newly discovered hormone with potential treatment for obesity, type 2 diabetes, liver disease

November 17, 2014
Researchers at the University of Michigan have discovered how a previously unknown hormone serves as a messenger from fat cells to the liver and are investigating the potential of developing a new treatment for metabolic ...

Of mice and cheeseburgers: Experimental drug reverses obesity-related liver disease

August 3, 2017
A drug developed at the University of Rochester Medical Center protected mice from one of the many ills of our cheeseburger and milkshake-laden Western diet—non-alcoholic fatty liver disease.

Recommended for you

Researchers make essential imaging tests safer for people at risk of acute kidney injury

October 15, 2018
Every year, millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes. "For the majority of patients, these are safe and necessary procedures. However, about ...

Medical marijuana might help MS patients, but uncertainty remains

October 13, 2018
Medical products derived from marijuana might have a mild benefit in treating symptoms of multiple sclerosis, based on reports from patients.

Do not give decongestants to young children for common cold symptoms, say experts

October 11, 2018
Decongestants should not be given to children under 6—and given with caution in children under 12—as there is no evidence that they alleviate symptoms such as a blocked or runny nose, and their safety is unclear, say ...

New techniques can detect Lyme disease weeks before current tests

October 11, 2018
Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

Pneumonia-causing bacteria can be spread by nose picking and rubbing

October 11, 2018
Pneumonia-causing bacteria can be spread through picking and rubbing the nose, according to new research published in the European Respiratory Journal.

Plant compound found to have therapeutic effect on complications from snakebites

October 11, 2018
Rutin, a flavonoid, may complement antivenom as an effective co-treatment for envenoming from Bothrops jaraca.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.